Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J Physiol Pharmacol ; 69(3)2018 Jun.
Article in English | MEDLINE | ID: mdl-30342432

ABSTRACT

The goal of this research was to examine the influence of chronic mild stress (CMS) on prepulse inhibition (PPI). We used an amphetamine challenge to study the role of the dopaminergic system in limbic structures. Chronic stress caused a reduction in both sucrose preference and body weight. It was found that the initially strong response to amphetamine in the control rats was weakened after stress on both the behavioural and biochemical levels: improved PPI, decreased dopamine D2 receptor expression in the central nucleus of amygdala (CeA) and nucleus accumbens (NAC), and decreased dopamine and 3-MT (3-methoxytyramine) levels in NAC. We observed that the stress-evoked attenuation of amphetamine-induced stimulation was also paralleled by changes in corticosterone level. These effects were accompanied by a decrease in both glutamate and the glutamate/gamma-aminobutric acid (GABA) ratio in the NAC. The interpretation of these results is that prolonged stress induces compensatory mechanisms in the mesolimbic system which are responsible for psychostimulant (amphetamine) effects.


Subject(s)
Amphetamine/pharmacology , Central Amygdaloid Nucleus/drug effects , Central Nervous System Stimulants/pharmacology , Nucleus Accumbens/drug effects , Prepulse Inhibition/drug effects , Receptors, Dopamine D2/physiology , Stress, Psychological/physiopathology , Animals , Central Amygdaloid Nucleus/physiology , Corticosterone/metabolism , Dopamine/metabolism , Glutamic Acid/metabolism , Male , Nucleus Accumbens/physiology , Rats, Wistar , Stress, Psychological/metabolism , gamma-Aminobutyric Acid/metabolism
2.
Br J Pharmacol ; 171(4): 973-84, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24199650

ABSTRACT

BACKGROUND AND PURPOSE: Many dementia patients exhibit behavioural and psychological symptoms (BPSD) that include psychosis, aggressivity, depression and anxiety. Antipsychotic drugs are frequently prescribed but fail to significantly attenuate mood deficits, may interfere with cognitive function and are associated with motor and cardiac side effects, which are problematic in elderly patients. A need therefore exists for drugs that are better suited for the treatment of BPSD. EXPERIMENTAL APPROACH: We used in vitro cellular and in vivo behavioural tests to characterize ADN-1184, a novel arylsulfonamide ligand with potential utility for treatment of BPSD. KEY RESULTS: ADN-1184 exhibits substantial 5-HT6 /5-HT7 /5-HT2A /D2 receptor affinity and antagonist properties in vitro. In tests of antipsychotic-like activity, it reversed MK-801-induced hyperactivity and stereotypies and inhibited conditioned avoidance response (MED = 3 mg·kg(-1) i.p.). Remarkably, ADN-1184 also reduced immobility time in the forced swim test at low doses (0.3 and 1 mg·kg(-1) i.p.; higher doses were not significantly active). Notably, up to 30 mg·kg(-1) ADN-1184 did not impair memory performance in the passive avoidance test or elicit significant catalepsy and only modestly inhibited spontaneous locomotor activity (MED = 30 mg·kg(-1) i.p.). CONCLUSIONS AND IMPLICATIONS: ADN-1184 combines antipsychotic-like with antidepressant-like properties without interfering with memory function or locomotion. This profile is better than that of commonly used atypical antipsychotics tested under the same conditions and suggests that it is feasible to identify drugs that improve BPSD, without exacerbating cognitive deficit or movement impairment, which are of particular concern in patients with dementia.


Subject(s)
Antipsychotic Agents/pharmacology , Isoxazoles/pharmacology , Receptors, Serotonin/metabolism , Serotonin Antagonists/pharmacology , Sulfonamides/pharmacology , Animals , Antipsychotic Agents/blood , Antipsychotic Agents/pharmacokinetics , Behavior, Animal/drug effects , Brain/metabolism , CHO Cells , Cricetulus , Dizocilpine Maleate/pharmacology , HEK293 Cells , Humans , Isoxazoles/blood , Isoxazoles/pharmacokinetics , Ligands , Male , Motor Activity/drug effects , Rats , Rats, Sprague-Dawley , Rats, Wistar , Serotonin Antagonists/blood , Serotonin Antagonists/pharmacokinetics , Sulfonamides/blood , Sulfonamides/pharmacokinetics
3.
Int Urogynecol J ; 24(12): 2087-92, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23749240

ABSTRACT

INTRODUCTION AND HYPOTHESIS: The aim of the present study was to determine possible correlations between mesh retraction after anterior vaginal mesh repair and de novo stress urinary incontinence (SUI), overactive bladder (OAB), and vaginal pain symptoms. METHODS: One hundred and three women with symptomatic prolapse of the anterior vaginal wall, stages 3 and 4 based on the Pelvic Organ Prolapse Quantification (POP-Q) system, underwent Prolift anterior™ implantation. At a 6-month follow-up, the patients were interviewed for de novo SUI, OAB, and vaginal pain, and underwent an introital/transvaginal ultrasound examination to measure the mesh length in the midsagittal plane. RESULTS: Mesh retraction was significantly larger in a subgroup of patients (n = 20; 19.4 %) presenting de novo OAB symptoms on the follow-up assessment compared with those without this complication (5.0 cm vs. 4.3 cm; p < 0.05). Mesh retraction was also significantly larger in a subgroup of patients (n = 23; 22.3 %) reporting postoperative vaginal pain compared with the women who did not report any postoperative vaginal pain (5.3 cm vs. 4.2 cm; p < 0.01). A significant correlation was found between mesh retraction and the severity of vaginal pain (R = 0.4, p < 0.01). Mesh retraction did not differ between patients with de novo SUI symptoms and those without this complication. CONCLUSIONS: Mesh retraction assessed on ultrasound examination after anterior vaginal mesh repair may correlate with de novo OAB symptoms and vaginal pain.


Subject(s)
Pain, Postoperative/etiology , Prosthesis Failure/adverse effects , Surgical Mesh/adverse effects , Urinary Bladder, Overactive/etiology , Urinary Incontinence, Stress/etiology , Uterine Prolapse/surgery , Vagina/surgery , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Polypropylenes , Suburethral Slings/adverse effects
4.
Genes Brain Behav ; 10(5): 551-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21429093

ABSTRACT

Inhibitory effects of passive ethanol exposure on brain neurogenesis have been extensively documented in animal models. In contrast, a role of brain neurogenesis in ethanol self-administration has not been addressed, as yet. The aim of this study was to assess intake of, and preference for, ethanol solutions [2-16% (v/v)] in a mouse model of adult neurogenesis deficiency based on permanent knockout (KO) of cyclin D2 (Ccnd2). Wild type (WT) and Ccnd2 KO mice did not differ in 2% and 4% ethanol intake. The KO group consumed significantly more ethanol in g/kg when offered with 8% or 16% ethanol as compared with the WT controls. The WT and KO mice did not differ in 2% ethanol preference, but the KO group showed a significantly higher preference for 4-16% ethanol. Animal and human studies have suggested that the low level of response to the sedative/hypnotic effects of alcohol is genetically associated with enhanced alcohol consumption. However, in this study, there were no between-genotype differences in ethanol-induced loss of righting reflex. Previous reports have also suggested that high ethanol intake is genetically associated with the avidity for sweets and better acceptance of bitter solutions. However, the KO and WT mice consumed similar amounts of saccharin solutions and the KOs consumed less quinine (i.e. bitter) solutions as compared with the WTs. In conclusion, these results may indicate that Ccnd2 and, possibly, brain neurogenesis are involved in central regulation of ethanol intake in mice.


Subject(s)
Alcohol Drinking/genetics , Choice Behavior/physiology , Cyclin D2/genetics , Ethanol/administration & dosage , Neurogenesis/genetics , Animals , Cyclin D2/metabolism , Genotype , Mice , Mice, Knockout , Self Administration
5.
J Physiol Pharmacol ; 60(3): 119-25, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19826190

ABSTRACT

Some empirical evidence suggests that the endocannabinoids (eCB) (e.g. anandamide) may play an important role in cocaine addiction. The eCB act as a retrograde messengers activating CB receptors at the presynaptic membrane and are degraded by enzymatic actions of fatty acid amide hydrolase (FAAH). The present study aimed to examine the effect of the FAAH inhibitors, phenylmethylsulphonyl fluoride (PMSF; i.p.) or cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester (URB597; i.p.) on the cocaine- or food-maintained self-administration as well as on the cocaine-seeking or food-taking behaviors in rats. Male Wistar rats were implanted with a catheter (iv.) and trained to self-administer cocaine (0.5 mg/kg/infusion) on a fixed ratio 5 schedule of reinforcement with a conditioned stimulus (tone+light). After self-administration stabilized, extinction/reinstatement procedures were carried out during which the rats were tested for the response reinstatement induced by cocaine (10 mg/kg, ip) or a cue (light+tone). The food (sweetened milk) self-administration and extinction/reinstatement procedures were conducted in a manner resembling cocaine self-administration. Neither PMSF (30-120 mg/kg) nor URB597 (0.1-3 mg/kg) affected cocaine self-administration. PMSF, 60 mg/kg, significantly reduced cocaine-induced reinstatement and at 120 mg/kg (combined with the challenge dose of cocaine) it evoked behavioral disruption. PMSF (60-120 mg/kg) dose-dependently inhibited cue-induced reinstatement. URB597 (1-3 mg/kg) attenuated both cocaine- and cue-induced drug-seeking behaviors. PMSF (60 mg/kg) decreased food self-administration. Toward reinstatement of food-taking behavior PMSF (60-120 mg/kg) and URB597 (3 mg/kg) showed inhibitory effects. Our results indicate that FAAH inhibitors could be potent modulators of motivational and conditioned aspects of goal-directed behaviors with less prominent effects on consumatory behaviors.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Behavior, Animal/drug effects , Cocaine-Related Disorders/psychology , Cocaine/administration & dosage , Eating/drug effects , Enzyme Inhibitors/pharmacology , Reinforcement, Psychology , Animals , Benzamides/administration & dosage , Benzamides/pharmacology , Carbamates/administration & dosage , Carbamates/pharmacology , Cocaine-Related Disorders/enzymology , Cocaine-Related Disorders/metabolism , Consummatory Behavior/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/administration & dosage , Extinction, Psychological/drug effects , Feeding Behavior/drug effects , Injections, Intraperitoneal , Male , Phenylmethylsulfonyl Fluoride/administration & dosage , Phenylmethylsulfonyl Fluoride/pharmacology , Rats , Rats, Wistar , Self Administration
6.
Eur J Neurol ; 12(1): 31-9, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15613144

ABSTRACT

The aim of our study was to estimate the costs of multiple sclerosis (MS) in Poland according to severity of disease. Total, direct and indirect costs were compared in 148 patients divided into three groups categorized by disease severity: stage I Expanded Disability Status Scale (EDSS <3.5), stage II (EDSS 4.0-6.0) and stage III (EDSS >6.5). Cost evaluation was performed from the societal perspective and covered the 5-month period. Simple sensitivity analysis was performed by varying the tariffs and valuing caregiving at 40% of the average wage. The mean total cost/patient for 5 months was estimated at 10,955, 15, 603 and 18, 464 PLN for stage I, II and III, respectively [exchange rate: 4 PLN=1 EUR; purchasing power pariety: 1 EUR=2.05 PLN] (P <0.0001). Regardless of EDSS stage indirect costs exceeded direct costs. Both direct and indirect costs increased with MS progression. For indirect cost the main item was productivity loss. This study confirms that MS represents a high economic burden, with indirect costs greatly exceeding direct costs. As costs increase with disease progression, treatment efforts should focus on patients in the early stages of MS.


Subject(s)
Health Care Costs , Multiple Sclerosis/economics , Multiple Sclerosis/epidemiology , Adult , Analysis of Variance , Costs and Cost Analysis/statistics & numerical data , Cross-Sectional Studies , Disability Evaluation , Female , Health Care Costs/statistics & numerical data , Humans , Male , Middle Aged , Multiple Sclerosis/therapy , Poland/epidemiology , Prospective Studies , Severity of Illness Index , Statistics, Nonparametric
7.
J Neurochem ; 91(1): 38-48, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15379885

ABSTRACT

Influence of morphine self-administration on gene expression in the rat amygdala was studied using rat genome DNA arrays U34A from Affymetrix. Animals were trained to self-administer morphine, each having two 'yoked' control animals, receiving passive injections of either morphine or saline. After 40 sessions of self-administration, amygdalae were removed, total RNA was isolated and used to prepare probes for Genechip arrays. The treatment was found to significantly change abundance of 29 transcripts. Analysis by means of reverse transcription real-time PCR showed significant changes in abundance of five transcripts: gamma protein kinase C (PKC), upstream binding factor 2 (UBF2), lysozyme, noggin and heat shock protein 70 (hsp70). After 30 days of forced abstinence from morphine self-administration, abundance of hsp70 and lysozyme returned to basal levels. Changes in abundance of UBF2 persisted, and abundance of three additional genes, namely nuclear factor I/A, gamma1 subunit of GABAA receptor and the neuronal calcium sensor 1, changed. Additionally, acute as well as chronic intraperitoneal morphine administration changed the abundance of PKC gamma, gamma1 subunit of GABAA and hsp70 genes.


Subject(s)
Amygdala/drug effects , Gene Expression/drug effects , Morphine/administration & dosage , Narcotics/administration & dosage , Amygdala/metabolism , Animals , Carrier Proteins , Drug Administration Schedule , HSP70 Heat-Shock Proteins/genetics , HSP70 Heat-Shock Proteins/metabolism , Injections, Intraperitoneal/methods , Male , Muramidase/genetics , Muramidase/metabolism , Neurofibromin 1/genetics , Neurofibromin 1/metabolism , Oligonucleotide Array Sequence Analysis/methods , Protein Kinase C/genetics , Protein Kinase C/metabolism , Proteins/genetics , Proteins/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/genetics , Receptors, GABA-A/metabolism , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction/methods , Self Administration/methods , Time Factors
8.
Eur J Neurol ; 7(5): 495-8, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11054133

ABSTRACT

Wilson's disease is an autosomal recessive disorder. More than 60 mutations of the Wilson's disease gene have been described so far. We have analysed 148 Polish Wilson's disease patients from 95 families for His1069Gln and Gly1267Lys mutations and correlated this finding with age and clinical form of the disease at presentation. To identify these mutations, single strand conformation polymorphism analysis was performed. In our group there were 94 patients with neurological presentation, 28 with hepatic presentation, whilst 26 were in a pre-clinical stage of the disease. His1069Gln mutation was present on 171 (57%) of the 296 studied chromosomes, and Gly1267Lys mutation was present on 27 chromosomes (9.1%). Most of our patients were homozygous or heterozygous for His1069Gln mutation (39.9% and 30.4%, respectively); 4% of the patients were homozygous for Gly1267Lys mutation and 5.4% had both of these described mutations on their chromosomes. His1069Gln and Gly1267Lys mutations occurred often in our Wilson's disease patient population but we did not find any relationship between investigated mutations and the clinical form of Wilson's disease or age of first symptoms.


Subject(s)
Gene Frequency/genetics , Hepatolenticular Degeneration/genetics , Mutation/genetics , Age Factors , DNA Mutational Analysis , Genotype , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/epidemiology , Humans , Poland/epidemiology
9.
Pol J Pharmacol ; 47(4): 313-20, 1995.
Article in English | MEDLINE | ID: mdl-8616510

ABSTRACT

Analgesia induced by cold water stress (CWS) was tested in the model of monolateral inflammation in spontaneously hypertensive (SHR), renal hypertensive (RHR) and normotensive Wistar (NR) and Wistar Kyoto (WKY) rats. Unilateral hind paw inflammation was induced by Freund's complete adjuvant (FCA). Four days after inoculation all tested rats exhibited profound analgesia following CWS in both inflamed and non-inflamed paws which reached a maximum immediately after CWS and returned to control values within 15 min. The activity of naloxone was tested both by systemic and local injection. Baseline pain thresholds of SHR rats were significantly higher than those of NR, WKY and RHR. Hyperalgesia following systemic intraperitoneal administration of naloxone applied ten minutes before CWS was higher in RHR and WKY than in NR and SHR. When administered directly into the inflamed paw, naloxone did not antagonize CWS-induced analgesia in RHR, in contrast to weak antagonism in NR, while more evident in SHR and WKY. Our results probably reflect biological and genetic variability of intrinsic opioid and inflammatory mechanisms in hypertension.


Subject(s)
Hindlimb/physiopathology , Hypertension/physiopathology , Naloxone/pharmacology , Temperature , Animals , Cold Temperature , Male , Rats , Rats, Inbred WKY , Rats, Wistar , Water
SELECTION OF CITATIONS
SEARCH DETAIL
...